Prosensa Holding NV Company Profile (NYSE:RNA)

About Prosensa Holding NV

Prosensa Holding NV logoProsensa Holding N.V., formerly Prosensa Holding B.V., is a biotechnology company engaged in the discovery and development of ribonucleic acid-modulating (RNA)-modulating, therapeutics for the treatment of genetic disorders. The Company's primary focus is on rare neuromuscular and neurodegenerative disorders with a large unmet medical need, including Duchenne muscular dystrophy, myotonic dystrophy and Huntington's disease. The Company's clinical portfolio of RNA-based product candidates is focused on the treatment of Duchenne muscular dystrophy (DMD). The Company's platform technology allows the development of RNA-modulating therapeutics that either interferes with splicing (exon skipping, exon inclusion, or splice mutation correction), remove mutant RNA, or block RNA expression, for different indications.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: NYSE
  • Symbol: RNA
  • CUSIP:
Key Metrics:
  • Previous Close: $19.00
  • 50 Day Moving Average: $19
  • 200 Day Moving Average: $17
  • 52-Week Range: $6.00 - $23.00
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -19.00
  • P/E Growth: 0
  • Market Cap: $N/A
Additional Links:

Analyst Ratings

Consensus Ratings for Prosensa Holding NV (NYSE:RNA) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Prosensa Holding NV (NYSE:RNA)
DateFirmActionRatingPrice TargetDetails
11/25/2014Credit Suisse Group AGBoost Price TargetNeutral$9.00 -> $20.00View Rating Details
11/25/2014Roth CapitalDowngradeBuy -> NeutralView Rating Details
11/25/2014KBC SecuritiesDowngradeBuy -> Hold$17.00 -> $19.80View Rating Details
(Data available from 10/22/2014 forward)


Earnings History for Prosensa Holding NV (NYSE:RNA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/17/2014Q314($0.25)($0.29)ViewN/AView Earnings Details
8/12/2014Q214($0.36)($0.29)ViewN/AView Earnings Details
5/20/2014Q114$0.01$0.26ViewN/AView Earnings Details
3/18/2014($0.14)($0.12)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Prosensa Holding NV (NYSE:RNA)
Current Year EPS Consensus Estimate: $-1 EPS
Next Year EPS Consensus Estimate: $-1 EPS


Dividend History for Prosensa Holding NV (NYSE:RNA)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Prosensa Holding NV (NYSE:RNA)
No insider trades for this company have been tracked by


Latest Headlines for Prosensa Holding NV (NYSE:RNA)
DateHeadline logoBioMarin Upgraded to Strong Buy, Is It in Your Portfolio? - Analyst Blog (NYSE:RNA) - April 29 at 4:32 PM logoHow bubbles are blown: Biotech edition (NYSE:RNA) - March 31 at 7:53 AM logoBioMarin Pharma Hits All-Time High (NYSE:RNA) - March 27 at 6:40 PM logoBioMarin Pharmaceutical Inc. (BMRN) and Other Top New Picks of Healthcare-Focused Visium Asset Management (NYSE:RNA) - March 3 at 10:09 AM logoWhy Muscular Dystrophy Is Biotech's Favorite Orphan (NYSE:RNA) - February 19 at 4:59 PM logoProsensa Announces Voluntary Delisting and Advance Liquidation Distribution (NYSE:RNA) - February 10 at 4:17 PM logoProsensa Announces Intent to Voluntarily Delist From NASDAQ (NYSE:RNA) - January 31 at 1:53 AM logoBioMarin Announces Final Results of Tender Offer for Prosensa's Shares and Completion of Subsequent Offering Period (NYSE:RNA) - January 30 at 8:09 AM logoBioMarin to Raise Funds to Finance Prosensa Acquisition - Analyst Blog (NYSE:RNA) - January 22 at 6:00 PM logoState Of The Union Lights Up Biotech (NYSE:RNA) - January 21 at 6:25 AM logoBioMarin Gains on Vimizim 2014 View, Batten Disease Data - Analyst Blog (NYSE:RNA) - January 14 at 5:10 PM logoProsensa Announces Shareholder Approval of Certain Matters Relating to the BioMarin Tender Offer (NYSE:RNA) - January 13 at 10:43 AM logoUS STOCKS-S&P 500 ticks up to record on central bank bets (NYSE:RNA) - November 24 at 4:49 PM logoUS STOCKS-Wall St up on central bank bets, deals support (NYSE:RNA) - November 24 at 3:19 PM logoUS STOCKS-Wall St hits new records, but telecom weighs on Dow (NYSE:RNA) - November 24 at 12:34 PM logoUS STOCKS-Wall St hits new records, boosted by cyclicals (NYSE:RNA) - November 24 at 11:18 AM logoBuying Glaxo's Biotech Stock Throwbacks Proves Profitable (NYSE:RNA) - November 24 at 10:57 AM logoUS STOCKS-Wall St surges to new records, boosted by cyclicals (NYSE:RNA) - November 24 at 10:04 AM logoBig News for Ebola Stocks (NYSE:RNA) - November 24 at 9:15 AM logoUS STOCKS-Futures point to higher open on merger activity (NYSE:RNA) - November 24 at 8:52 AM logoUS STOCKS-Futures rise, boosted by merger activity (NYSE:RNA) - November 24 at 8:14 AM logoBioMarin Pharma offers about $680M for Prosensa (NYSE:RNA) - November 24 at 7:35 AM logoBioMarin to buy Prosensa in $840 mln deal (NYSE:RNA) - November 24 at 6:24 AM


Prosensa Holding NV (NYSE:RNA) Chart for Saturday, October, 22, 2016

Last Updated on 10/22/2016 by Staff